Esperion Therapeutics (ESPR) Net Income Growth (5y) (2017 - 2026)
Esperion Therapeutics (ESPR) Net Income Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.93% |
| Dec 31, 2025 | 21.05% |
| Sep 30, 2025 | 17.84% |
| Jun 30, 2025 | -16.08% |
| Mar 31, 2025 | 11.98% |
| Dec 31, 2024 | 14.35% |
| Sep 30, 2024 | 14.92% |
| Jun 30, 2024 | 27.44% |
| Mar 31, 2024 | -7.70% |
| Dec 31, 2023 | 1.09% |
| Sep 30, 2023 | 19.94% |
| Jun 30, 2023 | 14.01% |
| Mar 31, 2023 | 22.13% |
| Dec 31, 2022 | -7.98% |
| Sep 30, 2022 | 19.00% |
| Jun 30, 2022 | 14.45% |
| Mar 31, 2022 | -6.84% |
| Dec 31, 2021 | -18.65% |
| Sep 30, 2021 | -31.26% |
| Jun 30, 2021 | -24.79% |